[HTML][HTML] Efficacy of oral cryotherapy on oral mucositis prevention in patients with hematological malignancies undergoing hematopoietic stem cell transplantation: a …
…, D Li, X Zhao, H Wei, Z Pang, L Wang, D Liu, Q Wang… - PloS one, 2015 - journals.plos.org
Objectives Controversy exists regarding whether oral cryotherapy can prevent oral mucositis
(OM) in patients with hematological malignancies undergoing hematopoietic stem cell …
(OM) in patients with hematological malignancies undergoing hematopoietic stem cell …
Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
…, X Li, Q Han, Y Guo, Y Zhang, Y Wang, C Wang… - …, 2015 - Taylor & Francis
The engineering of T lymphocytes to express chimeric antigen receptors (CARs) aims to
establish T cell-mediated tumor immunity rapidly. In this study, we conducted a pilot clinical trial …
establish T cell-mediated tumor immunity rapidly. In this study, we conducted a pilot clinical trial …
[HTML][HTML] Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
…, L Fan, J Zhou, D Zou, W Li, H Yang, T Liu, Q Wang… - Leukemia, 2020 - nature.com
Prognosis is poor for patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL)
after failure of or who are ineligible for autologous stem cell transplant. We evaluated the …
after failure of or who are ineligible for autologous stem cell transplant. We evaluated the …
[HTML][HTML] Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia
Q Wang, Y Wang, H Lv, Q Han, H Fan, B Guo, L Wang… - Molecular therapy, 2015 - cell.com
We conducted a clinical trial to assess the feasibility and efficacy of CD33-directed chimeric
antigen receptor-modified T cells (CART-33) for the treatment of refractory acute myeloid …
antigen receptor-modified T cells (CART-33) for the treatment of refractory acute myeloid …
Tislelizumab for relapsed/refractory classical Hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis
…, X Zhao, D Wang, P Zhang, Y Wang, L Wang… - Clinical Cancer …, 2022 - AACR
Purpose: Tislelizumab is an anti–programmed cell death protein 1 (anti–PD-1) monoclonal
antibody specifically designed to minimize binding to Fcγ receptors (FcγR). Patients and …
antibody specifically designed to minimize binding to Fcγ receptors (FcγR). Patients and …
Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells
Y Wang, W Zhang, Q Han, Y Liu, H Dai, Y Guo, J Bo… - Clinical …, 2014 - Elsevier
We conducted a trial testing a CD20-specific CAR coupled with CD137 and the CD3ζ
moiety in patients with chemotherapy refractory advanced diffuse large B cell lymphomas (DLBCL)…
moiety in patients with chemotherapy refractory advanced diffuse large B cell lymphomas (DLBCL)…
[HTML][HTML] The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single …
W Zhang, L Su, L Liu, Y Gao, Q Wang… - Cancer Biology & …, 2021 - ncbi.nlm.nih.gov
Objective: To assess the efficacy and safety of the novel histone deacetylase inhibitor,
chidamide, in combination with cyclophosphamide, doxorubicin, vincristine, etoposide, and …
chidamide, in combination with cyclophosphamide, doxorubicin, vincristine, etoposide, and …
[HTML][HTML] Bilineal extramedullary blast crisis as an initial presentation of chronic myeloid leukemia: a case report and literature review
…, J Li, L Wang, J Lin, H Jin, Y Xu, N Wang… - The American Journal …, 2016 - ncbi.nlm.nih.gov
Objective: Rare co-existance of disease or pathology Background: Chronic myeloid
leukemia (CML) is a clonal myeloproliferative disorder characterized by the Philadelphia …
leukemia (CML) is a clonal myeloproliferative disorder characterized by the Philadelphia …
The efficacy and safety of sirolimus‐based graft‐versus‐host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta …
…, X Zhao, H Wei, Z Pang, L Wang, D Liu, Q Wang… - …, 2015 - Wiley Online Library
BACKGROUND The efficacy and safety of sirolimus (SIR)‐based graft‐versus‐host disease
(GVHD) prophylaxis in patients who were subjected to allogeneic hematopoietic stem cell …
(GVHD) prophylaxis in patients who were subjected to allogeneic hematopoietic stem cell …
[HTML][HTML] Systemic and prophylactic intrathecal chemotherapy for primary adrenal lymphoma: A retrospective study of 20 case reports
L Yuan, L Sun, J Bo, Q Wang, Y Zhao - Medicine, 2019 - journals.lww.com
… Yuan, Lei MD a ; Sun, Lu MD b ; Bo, Jian MD a ; Wang, Quanshun MD a ; Zhao, Yu MD a,∗ …
Zhou L, Peng W, Wang C, et al. Primary adrenal lymphoma: radiological; pathological …
Zhou L, Peng W, Wang C, et al. Primary adrenal lymphoma: radiological; pathological …